model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Gemini-3-Pro,protocolSection.identificationModule.nctId,TP,TP,NCT03136861,NCT03136861,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.briefTitle,FN,FN,SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis,,False,0.0,,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,False,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.officialTitle,TP,TP,"A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis",Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial,True,0.94,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.briefSummary,TP,TP,"The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease flares in patients with axial spondyloarthritis (axSpA) who had an inadequate response to prior non-steroidal anti-inflammatory drugs (NSAIDs). This study also explored the efficacy and safety of secukinumab 300 mg compared to secukinumab 150 mg from Week 8 to Week 24 in order to assess the potential additional benefits of dose escalation in patients with axSpA.","This study, titled SKIPPAIN, evaluated the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with active axial spondyloarthritis (axSpA). The primary goal was to assess the superiority of secukinumab in achieving a significant reduction in spinal pain (average spinal pain score <4) by Week 8, with further evaluation of sustained improvement and safety up to Week 24.",True,0.9,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.detailedDescription,TP,TP,"The study consisted of 2 treatment periods: a double-blind, placebo-controlled period from Baseline to Week 8 (Treatment Period 1) and a double-blind secukinumab treatment period from Week 8 to Week 24 (Treatment Period 2).

At Baseline (Treatment Period 1), patients were randomized in a 3:1 ratio to either secukinumab 150 mg (Group A) or placebo (Group B). At Week 8 (Treatment Period 2), patients were re-randomized and re-assigned respectively to 1 of 5 treatment arms to receive either secukinumab 150 mg or secukinumab 300 mg.

Patients assigned to secukinumab 150 mg (Group A) at Baseline who were responders (i.e. spinal pain score \< 4) at Week 8 continued on the same dose until Week 24 under 1 treatment arm (Arm A1). Patients assigned to secukinumab 150 mg at Baseline who were non-responders at Week 8 were re-randomized to 1 of 2 treatment arms: secukinumab 150 mg (Arm A2) or secukinumab 300 mg (Arm A3) from Week 8 to Week 24.

Similarly, patients assigned to placebo (Group B) at Baseline were re-randomized to 1 of 2 treatment arms: secukinumab 150 mg (Arm B1) or secukinumab 300 mg (Arm B2) from Week 8 until Week 24.","SKIPPAIN is a randomized, double-blind, placebo-controlled, multicenter study designed to assess secukinumab in patients with axial spondyloarthritis (axSpA), including both radiographic (r-axSpA) and non-radiographic (nr-axSpA) forms. Eligible patients were adults with active spinal disease defined by a BASDAI score ≥4 and an average spinal pain score >4, who had an inadequate response to NSAIDs.

The study consisted of two periods. In Treatment Period 1 (TP1), patients were randomized (3:1) to receive either secukinumab 150 mg (Group A) or placebo (Group B) from baseline to Week 8. At Week 8, patients entered Treatment Period 2 (TP2). Responders in Group A (average spinal pain score <4) continued on secukinumab 150 mg. Non-responders in Group A were re-randomized to either continue secukinumab 150 mg or escalate to 300 mg (up-titration). Patients in the placebo group were re-randomized to receive secukinumab 150 mg or 300 mg. The primary endpoint was the proportion of patients achieving an average spinal pain score <4 on a 0–10 numerical rating scale (NRS) at Week 8. Secondary endpoints included BASDAI scores and safety assessments.",True,0.96,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.conditions,TP,FP,['Spondyloarthritis'],"['Axial Spondyloarthritis', 'Ankylosing Spondylitis', 'Non-radiographic Axial Spondyloarthritis', 'Spinal Pain']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.keywords,TP,FP,"['axial spondyloarthritis', 'ankylosing spondylitis', 'non-radiographic axial spondyloarthritis', 'inflammatory back pain', 'spinal pain', 'secukinumab', 'AIN457']","['Secukinumab', 'axSpA', 'Spinal pain', 'Biological DMARDs', 'IL-17 inhibitor', 'BASDAI', 'Placebo-controlled', 'Inflammation']",False,0.2857142857142857,partial,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.phases,TP,TP,['PHASE3'],['PHASE3'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"The study consisted of two treatment periods: a double-blind, placebo-controlled period from baseline to Week 8 (TP1) and a double-blind secukinumab treatment period from Week 8 to Week 24 (TP2). Eligible patients were randomized (3:1) to receive either secukinumab 150 mg or placebo in TP1. At Week 8, patients were re-randomized or re-assigned to one of five treatment arms based on response status.",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,QUADRUPLE,DOUBLE,True,0.7,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"The study is described as double-blind. The identity of the treatments was concealed using study drugs (active and placebo) that were all identical in packaging, labelling, schedule of administration, and appearance.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.whoMasked,FN,FN,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']",,False,0.0,,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,False,False,False,False
Gemini-3-Pro,protocolSection.designModule.enrollmentInfo.count,TP,TP,383,380,True,0.98,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Proportion of patients achieving a spinal pain score of <4 (NRS),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Proportion of patients achieving a BASDAI score of <4,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Proportion of patients achieving ASDAS <2.1 and ASDAS <1.3,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[3].measure,EV,EV,,Mean change from baseline in FACIT-Fatigue score,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[4].measure,EV,EV,,ASAS health index (ASAS-HI),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[5].measure,EV,EV,,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Average spinal pain score measured on a 0–10 numerical rating scale.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of less than 4.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,Ankylosing Spondylitis Disease Activity Score (ASDAS) indicating low disease activity (<2.1) and inactive disease (<1.3).,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[3].description,EV,EV,,Functional Assessment of Chronic Illness Therapy-Fatigue score.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[4].description,EV,EV,,Assessment of SpondyloArthritis international Society health index.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[5].description,EV,EV,,"Assessment of overall safety and tolerability including AEs, SAEs, and AEs of special interest.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,"Weeks 1, 2, 3, 4, and 24",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,Week 24,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,Week 8 and Week 24,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[3].timeFrame,EV,EV,,Week 8 and Week 24,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[4].timeFrame,EV,EV,,Week 24,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[5].timeFrame,EV,EV,,From baseline through Week 24 (TP1 and TP2) and up to 12 weeks after last study treatment,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Key Inclusion Criteria:

* Diagnosis of axial spondylarthritis (axSpA, either ankylosing spondylitis or non radiographic axial spondylarthritis) according to ASAS axSpA classification criteria
* patients with back pain for at least 3 months and age of onset less than 45 years
* Active axSpA as assessed by total BASDAI score of at least 4 at Baseline.
* Spinal pain numeric rating scale score of more than 4 at Baseline.
* inadequate response to or failure to respond to at least 2 different NSAIDs at the highest recommended dose for at least 4 weeks in total prior to randomization

Key Exclusion Criteria:

* Chest X-ray or MRI with evidence of ongoing infectious or malignant process
* Patients previously treated with any biological immunomodulating agents, except those targeting tumor necrosis factor alpha.
* Patients who have been exposed to more than one anti-tumor necrosis factor alpha agent.
* Active ongoing inflammatory diseases other than axial spondyloarthritis
* Other ongoing mechanical diseases affecting the spine.","Inclusion Criteria:
- Male and female patients of >=18 years with a diagnosis of axSpA, classified as nr-axSpA or r-axSpA according to the Assessment of SpondyloArthritis international Society (ASAS) criteria.
- Active spinal disease defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of >=4 and average spinal pain score of >4.
- Inadequate response to the highest recommended dose of at least two NSAIDs over a period of >=4 weeks; in the case of toxicity, intolerance, or contraindications, this period was shorter.
- Patients on regular NSAIDs as part of their axSpA therapy were required to be on a stable dose for >=2 weeks before randomization.
- Patients previously on a TNFi were also allowed to enter the trial but should have had an appropriate washout period prior to randomization.

Exclusion Criteria:
- Previous treatment or exposure to any biological immunomodulating agents, except one TNF-alpha inhibitor agent.
- Current and active inflammatory diseases other than axSpA.
- Any mechanical disease that affects the spine.
- Any active systemic infections.
- History of chronic or recurrent infectious disease.
- History of any known malignancy within the past 5 years.
- Serious medical conditions, such as uncontrolled hypertension or congestive heart failure.
- Any underlying conditions that could compromise the immune system.",True,0.94,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
